The CRISPR-powered Diagnostic SLEUTH - Scorecard - MDSpire

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min

Share

Clinical Scorecard: The CRISPR-powered Diagnostic SLEUTH

At a Glance

CategoryDetail
ConditionRNA detection and diagnostics
Key MechanismsDNA-guided Cas12a system for RNA targeting
Target PopulationClinical samples, including SARS-CoV-2
Care SettingLaboratory and potential clinical diagnostics

Key Highlights

  • Modified CRISPR–Cas12a system uses DNA guides for RNA detection
  • Accurate recognition and cleavage of single-stranded RNA
  • Diagnostic workflow SLEUTH shows complete agreement with RT-qPCR
  • System can distinguish single-nucleotide sequence differences
  • Demonstrated targeted RNA reduction in living cells

Guideline-Based Recommendations

Diagnosis

  • Use of DNA-guided Cas12a for RNA-targeted diagnostics

Management

  • Applications in mutation detection and precision diagnostics

Monitoring & Follow-up

  • Further optimization of the DNA-guided system is required

Risks

  • Less stability of DNA-guided complexes compared to RNA-guided systems

Patient & Prescribing Data

SARS-CoV-2 clinical samples

RNA-targeted therapies using DNA guides

Clinical Best Practices

  • Consider DNA-guided systems for RNA detection in diagnostics
  • Evaluate stability and efficacy in clinical settings

Related Resources & Content

Original Source(s)

The CRISPR-powered Diagnostic SLEUTH

  • May 22, 2026

Related Content

Can AI Aid Urine Drug Test Sign-Outs?

Researchers reported that an artificial intelligence workflow maintained high interpretive accuracy while reducing urine drug test sign-out time in a supervised clinical laboratory setting.

Breast Cancer Protocols Move Forward

WHO-aligned updates affect synoptic reporting, grading, and tumor characterization

  • July 7, 2026

  • 2 min
Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.